SEC Form 4 · accession 0001179110-15-016421

GILEAD SCIENCES, INC. · GILD

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP, R&D and CSO

Period of report

Dec 15, 2015

Accepted (ET)

Dec 17, 2015 · 3:40 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000882095

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Dec 15, 2015	M	43,600	$23.755	A	171,536	D
Common Stock	Dec 15, 2015	M	26,400	$19.085	A	197,936	D
Common Stock^F4	Dec 15, 2015	S	30,431	$102.6571	D	167,505	D
Common Stock^F3	Dec 15, 2015	S	39,569	$102.221	D	127,936	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-Qualified Stock Option (right to buy)^F5	$19.085	Dec 15, 2015	M	26,400	D	—	Jan 20, 2021	Common Stock	26,400	211,600	D
Non-Qualified Stock Option (right to buy)^F2	$23.755	Dec 15, 2015	M	43,600	D	—	Jan 28, 2020	Common Stock	43,600	28,800	D

F1The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
F2The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
F3Sale prices reported for the transactions reported here range from $101.46 to $102.45. Full information regarding the number of shares purchased or sold at each separate p2rice will be provided to the SEC, the issuer or its shareowners upon request
F4Sale prices reported for the transactions reported here range from $102.46 to $102.99. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
F5The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.